VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
- Q3 2020 Total net product sales of $60.3 million, a 1% increase compared to Q3 2019   - Total net product sales for the first nine months of 2020 grew to $180.5 million, a 9% increase compared to the same period in 2019   - The HETLIOZ® Smith-Magenis Syndrome marketing authorization applications
View HTML
Toggle Summary Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
WASHINGTON , Oct. 26, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activator
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
Conference Call and Webcast to Follow WASHINGTON , Oct. 21, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Provides Update on Tradipitant Development Program
WASHINGTON , Aug. 31, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant. Enrollment in Vanda's Phase III clinical study (VP-VLY-686-3303) in gastroparesis is expected to be completed in the first half of 2021
View HTML
Toggle Summary Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
WASHINGTON , Aug. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 (COVID-19) pneumonia in the ODYSSEY study. Interim analysis of the ODYSSEY study showed that a 14
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
- Q2 2020 Total net product sales reached a new record of $62.2 million, a 7% increase as compared to Q1 2020   - Q2 2020 HETLIOZ® net product sales reached a new record of $41.6 million, an 18% increase as compared to Q1 2020   - The HETLIOZ® SMS marketing authorization applications were accepted
View HTML
Toggle Summary FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
WASHINGTON , Aug. 3, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda's applications for Smith-Magenis Syndrome (SMS). The applications include a Supplemental New Drug
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
Conference Call and Webcast to Follow WASHINGTON , July 29, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020 , after the market closes.
View HTML
Toggle Summary FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
WASHINGTON , July 13, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303).  This patient had previously
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
WASHINGTON , May 26, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to
View HTML
Toggle Summary Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
WASHINGTON , May 20, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company. On May 19, 2020 , Judge Amit P.
View HTML
Toggle Summary Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir
WASHINGTON , May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos , M.D., President and CEO of Vanda Pharmaceuticals , proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery and
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
WASHINGTON , May 13, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020 , it has reached agreement with the FDA to resubmit its application for
View HTML
Toggle Summary Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results
- Q1 2020 Total net product sales of $58.0 million, a 22% increase year over year - Advancing the Commercial and Development Pipeline; Initiating Studies for COVID-19 WASHINGTON , May 6, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced financial and
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020
Conference Call and Webcast to Follow WASHINGTON , April 29, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
WASHINGTON , April 15, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 ("COVID-19") infection and disease progression.
View HTML
Toggle Summary Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
WASHINGTON , April 15, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health's research arm, The Feinstein Institutes for Medical Research , today announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday
View HTML
Toggle Summary Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
WASHINGTON , April 8, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
WASHINGTON , April 2, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation
View HTML
Toggle Summary Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis
- Tradipitant antipruritic effects not seen in moderate or severe Atopic Dermatitis and the study did not meet its primary endpoint - Tradipitant significantly improved severe itch and nighttime sleep in patients with mild Atopic Dermatitis - Pruritus improved in over 70% of patients with mild
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
- Full year 2019 total revenues grew to $227.2 million, an 18% increase compared to 2018 - Full year 2020 total revenues expected to be between $240 million and $260 million - Results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis reported today WASHINGTON ,
View HTML
Toggle Summary Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors
WASHINGTON , Feb. 19, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announces the appointment of Stephen Ray Mitchell , M.D. to its Board of Directors. "Ray is a highly respected leader in academic medicine and globally recognized expert in Pediatrics," said Mihael H.
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Conference Call and Webcast to Follow WASHINGTON , Feb. 18, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020 , after the market closes.   Vanda will host a
View HTML
Toggle Summary Vanda Pharmaceuticals Comments on Court Ruling
WASHINGTON , Jan. 31, 2020 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration ( FDA ) v. Vanda, in which the U.S. District Court for the District of Columbia ruled in favor
View HTML
Toggle Summary Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
WASHINGTON , Jan. 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals (West-Ward), a subsidiary of Hikma Pharmaceuticals , relating to Vanda's U.S.
View HTML
Copyright © 2005-2020 Vanda Pharmaceuticals Inc. |